Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
暂无分享,去创建一个
Palle Petersen | Gregory W Albers | Alec Vahanian | Hans-Christoph Diener | H. Diener | J. Halperin | S. Olsson | G. Albers | A. Vahanian | J. Horrow | P. Petersen | S Bertil Olsson | Lars Frison | Jonathan L Halperin | L. Frison | M. Grind | M. Nevinson | S. Partridge | Jay Horrow | Margaretha Grind | Mark Nevinson | Stephen Partridge
[1] J. Haybittle,et al. Repeated assessment of results in clinical trials of cancer treatment. , 1971, The British journal of radiology.
[2] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[3] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[4] D. Wade,et al. The Barthel ADL Index: a reliability study. , 1988, International disability studies.
[5] J. Slattery,et al. Interobserver agreement for the assessment of handicap in stroke patients. , 1989, Stroke.
[6] R. Asinger,et al. Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. , 1989, Archives of neurology.
[7] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.
[8] G. Albers,et al. Atrial fibrillation and stroke. Three new studies, three remaining questions. , 1994, Archives of internal medicine.
[9] J. Hirsh,et al. Interactions of Warfarin with Drugs and Food , 1994, Annals of Internal Medicine.
[10] W. J. Hamilton,et al. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.
[11] A. Ebbutt,et al. Practical issues in equivalence trials. , 1998, Statistics in medicine.
[12] D. Singer,et al. Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 1999, Annals of Internal Medicine.
[13] F. McAlister,et al. Why do patients with atrial fibrillation not receive warfarin? , 2000, Archives of internal medicine.
[14] D. Witter,et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. , 2000, Archives of internal medicine.
[15] R. Hart,et al. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 2000 .
[16] M. Rosenqvist,et al. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. , 2001, European heart journal.
[17] D. Singer,et al. Antithrombotic therapy in atrial fibrillation. , 2001, Chest.
[18] V. Fuster,et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation , 2001 .
[19] B. Eriksson,et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial , 2002, The Lancet.
[20] W. Weaver,et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial , 2003, The Lancet.
[21] L. Johansson,et al. Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor , 2003, Clinical pharmacokinetics.
[22] Ulf Bredberg,et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects , 2003, European Journal of Clinical Pharmacology.
[23] J. Halperin,et al. Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality. , 2003, American heart journal.
[24] J. Rak,et al. The benefit‐to‐risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model , 2003, Journal of thrombosis and haemostasis : JTH.
[25] B. Eriksson,et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement , 2003, Thrombosis and Haemostasis.
[26] T. Andersson,et al. Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions , 2003, Clinical pharmacokinetics.
[27] P. Petersen,et al. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. , 2003, Journal of the American College of Cardiology.
[28] U. Eriksson,et al. No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran , 2003, Clinical pharmacokinetics.
[29] S. Schulman,et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. , 2003, The New England journal of medicine.
[30] F. Rosendaal,et al. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. , 2003, Archives of internal medicine.
[31] C. Colwell,et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. , 2003, The New England journal of medicine.
[32] M. Woodward,et al. Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History: The PROGRESS Trial , 2003, Stroke.